Memantine for Preservation of Neurocognitive Function During Reirradiation of Recurrent Glioblastoma
Date of Award
Spring 4-19-2024
Document Type
Open Access Thesis
Degree Name
Master of Medical Science (MMSc)
First Advisor
Mary Michele Barden, MD
Abstract
Glioblastoma is the most common malignant primary brain tumor in adults. This disease has a dismal prognosis with a median overall survival between 12-18 months. Recent analyses of salvage therapies for recurrence suggest that reirradiation may improve survival. A possible adverse effect is radiation-induced neurocognitive decline. There is a dearth of literature investigating neuroprotective strategies, like using memantine. Our aim is to investigate whether memantine protects neurocognitive function in this population, with an additional goal to show that memantine does not reduce overall and progression free survival. Subjects were randomly assigned to reirradiation plus memantine or reirradiation alone, and the Wilcoxon rank sum test was used to compare the median difference from baseline in the Hopkins scores at 24 weeks. Median progression free and overall survival were calculated using the Kaplan-Meier analysis. This study may provide insight on improving quality of life and reducing caregiver burden and corticosteroid usage.
Recommended Citation
Hiroi, Yeun, "Memantine for Preservation of Neurocognitive Function During Reirradiation of Recurrent Glioblastoma" (2024). Yale School of Medicine Physician Associate Program Theses. 206.
https://elischolar.library.yale.edu/ysmpa_theses/206
Comments
This is an open access thesis.